;PMID: 7379042
;source_file_881.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..34] = [t:0..34]
;1)sentence:[e:40..151] = [t:40..151]
;2)section:[e:155..190] = [t:155..190]
;3)sentence:[e:194..415] = [t:194..415]
;4)sentence:[e:416..615] = [t:416..615]
;5)sentence:[e:616..756] = [t:616..756]
;6)sentence:[e:757..855] = [t:757..855]
;7)sentence:[e:856..963] = [t:856..963]
;8)sentence:[e:964..1037] = [t:964..1037]
;9)sentence:[e:1038..1183] = [t:1038..1183]
;10)section:[e:1187..1231] = [t:1187..1231]

;section 0 Span:0..34
;Cancer Lett. 1980 Apr;9(2):123-31.
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..11] Lett) (.:[11..12] .) (CD:[13..17] 1980)
        (CC:[18..24] Apr;9-LRB-) (CD:[24..25] 2) (-RRB-:[25..26] -RRB-)
        (CD:[26..30] :123) (::[30..31] -) (CD:[31..33] 31) (.:[33..34] .)))

;sentence 1 Span:40..151
;Characterization of the guinea pig liver microsomal 2-fluorenylamine and 
;N-2-fluorenylacetamide N-hydroxylase.
;[92..108]:substance:"2-fluorenylamine"
;[114..150]:substance:"N-2-fluorenylacetamide N-hydroxylase"
(SENT
  (NP-HLN
    (NP (NN:[40..56] Characterization))
    (PP (IN:[57..59] of)
      (NP (DT:[60..63] the)
        (NML
          (NML
            (NML-1 (NN:[64..70] guinea) (NN:[71..74] pig))
            (NML-2 (NN:[75..80] liver))
            (ADJP-3 (JJ:[81..91] microsomal))
            (NN:[92..108] 2-fluorenylamine)
            (NML-4 (-NONE-:[108..108] *P*)))
          (CC:[109..112] and)
          (NML
            (NML-1 (-NONE-:[112..112] *P*))
            (NML-2 (-NONE-:[112..112] *P*))
            (ADJP-3 (-NONE-:[112..112] *P*))
             (NN:[114..136] N-2-fluorenylacetamide)
            (NML-4 (NN:[137..150] N-hydroxylase))))))
    (.:[150..151] .)))

;section 2 Span:155..190
;Razzouk C, Mercier M, Roberfroid M.
(SEC
  (FRAG (NNP:[155..162] Razzouk) (NNP:[163..164] C) (,:[164..165] ,)
        (NNP:[166..173] Mercier) (NNP:[174..176] M,) (NNP:[177..187] Roberfroid)
        (NNP:[188..190] M.)))

;sentence 3 Span:194..415
;Many reports in the literature have indicated that the guinea-pig is
;resistant  to the carcinogenic effect of N-2-fluorenylacetamide (2FAA); this
;refractoriness  has been attributed to its lack of N-hydroxylating enzymes.
;[304..326]:substance:"N-2-fluorenylacetamide"
;[328..332]:substance:"2FAA"
;[391..414]:substance:"N-hydroxylating enzymes"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (JJ:[194..198] Many) (NNS:[199..206] reports))
        (PP (IN:[207..209] in)
          (NP (DT:[210..213] the) (NN:[214..224] literature))))
      (VP (VBP:[225..229] have)
        (VP (VBN:[230..239] indicated)
          (SBAR (IN:[240..244] that)
            (S
              (NP-SBJ (DT:[245..248] the) (NN:[249..255] guinea)
                      (HYPH:[255..256] -) (NN:[256..259] pig))
              (VP (VBZ:[260..262] is)
                (ADJP-PRD (JJ:[263..272] resistant)
                  (PP (TO:[274..276] to)
                    (NP
                      (NP (DT:[277..280] the) (JJ:[281..293] carcinogenic)
                          (NN:[294..300] effect))
                      (PP (IN:[301..303] of)
                        (NP
                          (NP (NN:[304..326] N-2-fluorenylacetamide))
                          (NP (-LRB-:[327..328] -LRB-) (NN:[328..332] 2FAA)
                              (-RRB-:[332..333] -RRB-)))))))))))))
    (::[333..334] ;)
    (S
      (NP-SBJ-1 (DT:[335..339] this) (NN:[340..354] refractoriness))
      (VP (VBZ:[356..359] has)
        (VP (VBN:[360..364] been)
          (VP (VBN:[365..375] attributed)
            (NP-1 (-NONE-:[375..375] *))
            (PP-CLR (TO:[376..378] to)
              (NP
                (NP (PRP$:[379..382] its) (NN:[383..387] lack))
                (PP (IN:[388..390] of)
                  (NP (VBG:[391..406] N-hydroxylating) (NNS:[407..414] enzymes)))))))))
    (.:[414..415] .)))

;sentence 4 Span:416..615
;The present  communication, however, supports the results of contradictory
;reports which  demonstrate that guinea-pig liver microsomes are in fact able
;to N-hydroxylate  both 2-fluorenamine and 2FAA.
;[591..605]:substance:"2-fluorenamine"
;[610..614]:substance:"2FAA"
(SENT
  (S
    (NP-SBJ (DT:[416..419] The) (JJ:[420..427] present)
            (NN:[429..442] communication))
    (,:[442..443] ,)
    (ADVP (RB:[444..451] however))
    (,:[451..452] ,)
    (VP (VBZ:[453..461] supports)
      (NP
        (NP
          (NP (DT:[462..465] the) (NNS:[466..473] results))
          (PP (IN:[474..476] of)
            (NP (JJ:[477..490] contradictory) (NNS:[491..498] reports))))
        (SBAR
          (WHNP-1 (WDT:[499..504] which))
          (S
            (NP-SBJ-1 (-NONE-:[504..504] *T*))
            (VP (VBP:[506..517] demonstrate)
              (SBAR (IN:[518..522] that)
                (S
                  (NP-SBJ-2
                    (NML (NN:[523..529] guinea) (HYPH:[529..530] -)
                         (NN:[530..533] pig))
                    (NN:[534..539] liver) (NNS:[540..550] microsomes))
                  (VP (VBP:[551..554] are)
                    (PP (IN:[555..557] in)
                      (NP (NN:[558..562] fact)))
                    (ADJP-PRD (JJ:[563..567] able)
                      (S
                        (NP-SBJ-2 (-NONE-:[567..567] *))
                        (VP (TO:[568..570] to)
                          (VP (VB:[571..584] N-hydroxylate)
                            (NP (CC:[586..590] both)
                                (NN:[591..605] 2-fluorenamine)
                                (CC:[606..609] and) (NN:[610..614] 2FAA))))))))))))))
    (.:[614..615] .)))

;sentence 5 Span:616..756
;The guinea-pig N-hydroxylase activity toward  2-fluorenamine is found to be
;even greater than the reported activity in the rat  and hamster.
;[631..644]:substance:"N-hydroxylase"
;[662..676]:substance:"2-fluorenamine"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[616..619] The)
        (NML (NN:[620..626] guinea) (HYPH:[626..627] -) (NN:[627..630] pig))
        (NN:[631..644] N-hydroxylase) (NN:[645..653] activity))
      (PP (IN:[654..660] toward)
        (NP (NN:[662..676] 2-fluorenamine))))
    (VP (VBZ:[677..679] is)
      (VP (VBN:[680..685] found)
        (S
          (NP-SBJ-1 (-NONE-:[685..685] *))
          (VP (TO:[686..688] to)
            (VP (VB:[689..691] be)
              (ADJP-PRD
                (ADJP (RB:[692..696] even) (JJR:[697..704] greater))
                (PP (IN:[705..709] than)
                  (NP
                    (NP (DT:[710..713] the) (JJ:[714..722] reported)
                        (NN:[723..731] activity))
                    (PP-LOC (IN:[732..734] in)
                      (NP (DT:[735..738] the) (NN:[739..742] rat)
                          (CC:[744..747] and) (NN:[748..755] hamster)))))))))))
    (.:[755..756] .)))

;sentence 6 Span:757..855
;It is similarly inhibited by 3-methylcholanthrene (3MC),  7,8-benzoflavone
;(7,8 BF) or miconazole.
;[786..806]:substance:"3-methylcholanthrene"
;[808..811]:substance:"3MC"
;[815..831]:substance:"7,8-benzoflavone"
;[833..839]:substance:"7,8 BF"
;[844..854]:substance:"miconazole"
(SENT
  (S
    (NP-SBJ-1 (PRP:[757..759] It))
    (VP (VBZ:[760..762] is)
      (ADVP (RB:[763..772] similarly))
      (VP (VBN:[773..782] inhibited)
        (NP-1 (-NONE-:[782..782] *))
        (PP (IN:[783..785] by)
          (NP-LGS
            (NP
              (NP (NN:[786..806] 3-methylcholanthrene))
              (NP (-LRB-:[807..808] -LRB-) (NN:[808..811] 3MC)
                  (-RRB-:[811..812] -RRB-)))
            (,:[812..813] ,)
            (NP
              (NP (NN:[815..831] 7,8-benzoflavone))
              (NP (-LRB-:[832..833] -LRB-)
                 (NN:[833..836] 7,8) (NN:[837..839] BF)
                (-RRB-:[839..840] -RRB-)))
            (CC:[841..843] or)
            (NP (NN:[844..854] miconazole))))))
    (.:[854..855] .)))

;sentence 7 Span:856..963
;Activity toward N-2-fluorenacetamide is  present in the microsomal
;preparation from the control guinea-pig.
;[872..892]:substance:"N-2-fluorenacetamide"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[856..864] Activity))
      (PP (IN:[865..871] toward)
        (NP (NN:[872..892] N-2-fluorenacetamide))))
    (VP (VBZ:[893..895] is)
      (ADJP-PRD (JJ:[897..904] present))
      (PP-LOC (IN:[905..907] in)
        (NP
          (NP (DT:[908..911] the) (JJ:[912..922] microsomal)
              (NN:[923..934] preparation))
          (PP (IN:[935..939] from)
            (NP (DT:[940..943] the) (NN:[944..951] control)
                (NN:[952..958] guinea) (HYPH:[958..959] -) (NN:[959..962] pig))))))
    (.:[962..963] .)))

;sentence 8 Span:964..1037
;There is  slight activation by SKF525A, paraoxon (PX) or sodium fluoride.
;[995..1002]:substance:"SKF525A"
;[1004..1012]:substance:"paraoxon"
;[1014..1016]:substance:"PX"
;[1021..1036]:substance:"sodium fluoride"
(SENT
  (S
    (NP-SBJ (EX:[964..969] There))
    (VP (VBZ:[970..972] is)
      (NP-PRD
        (NP (JJ:[974..980] slight) (NN:[981..991] activation))
        (PP (IN:[992..994] by)
          (NP
            (NP (NN:[995..1002] SKF525A))
            (,:[1002..1003] ,)
            (NP
              (NP (NN:[1004..1012] paraoxon))
              (NP (-LRB-:[1013..1014] -LRB-) (NN:[1014..1016] PX)
                  (-RRB-:[1016..1017] -RRB-)))
            (CC:[1018..1020] or)
            (NP (NN:[1021..1027] sodium) (NN:[1028..1036] fluoride))))))
    (.:[1036..1037] .)))

;sentence 9 Span:1038..1183
;Under optimum  conditions, in the presence of both paraoxon and sodium
;fluoride, activity is  equivalent to that of rat liver microsomal enzymes.
;[1089..1097]:substance:"paraoxon"
;[1102..1117]:substance:"sodium fluoride"
;[1175..1182]:substance:"enzymes"
(SENT
  (S
    (PP (IN:[1038..1043] Under)
      (NP (JJ:[1044..1051] optimum) (NNS:[1053..1063] conditions)))
    (,:[1063..1064] ,)
    (PP (IN:[1065..1067] in)
      (NP
        (NP (DT:[1068..1071] the) (NN:[1072..1080] presence))
        (PP (IN:[1081..1083] of)
          (NP (CC:[1084..1088] both)
            (NP (NN:[1089..1097] paraoxon))
            (CC:[1098..1101] and)
            (NP (NN:[1102..1108] sodium) (NN:[1109..1117] fluoride))))))
    (,:[1117..1118] ,)
    (NP-SBJ (NN:[1119..1127] activity))
    (VP (VBZ:[1128..1130] is)
      (ADJP-PRD (JJ:[1132..1142] equivalent)
        (PP (TO:[1143..1145] to)
          (NP
            (NP (DT:[1146..1150] that))
            (PP (IN:[1151..1153] of)
              (NP (NN:[1154..1157] rat) (NN:[1158..1163] liver)
                  (JJ:[1164..1174] microsomal) (NNS:[1175..1182] enzymes)))))))
    (.:[1182..1183] .)))

;section 10 Span:1187..1231
;PMID: 7379042 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1187..1191] PMID) (::[1191..1192] :) (CD:[1193..1200] 7379042)
        (NN:[1201..1202] -LSB-) (NNP:[1202..1208] PubMed) (::[1209..1210] -)
        (NN:[1211..1218] indexed) (IN:[1219..1222] for)
        (NNP:[1223..1231] MEDLINE-RSB-)))
